Patents by Inventor Daniel Shao-Weng TAN

Daniel Shao-Weng TAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of biomarkers in determining susceptibility to disease treatment
    Patent number: 11274348
    Abstract: The present invention refers to a method of predicting susceptibility of a subject suffering from cancer to a treatment with an anti-cancer drug, wherein the method comprises detecting the presence or absence of a genetic alteration in a long non-coding RNA (IncRNA) that resides in an antisense strand of an oncogene, wherein the genetic alteration disrupts expression of the oncogene, and wherein the subject is predicted to be more susceptible to the treatment if the genetic alteration is present. In particular, the genetic alteration is a silent G>A mutation at Q787Q of the oncogene epidermal growth factor receptor (EGFR). Also disclosed herein is a method of treating a subject suffering from cancer, who was shown to have a genetic alteration in IncRNA that resides in an antisense strand of an oncogene.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 15, 2022
    Assignee: Singapore Health Services Pte Ltd
    Inventors: Narayanan Gopalakrishna Iyer, Daniel Shao-Weng Tan
  • NEW THERAPEUTIC USES
    Publication number: 20210145842
    Abstract: The present invention provides nazartinib, or a pharmaceutically acceptable salt thereof, preferably the mesylate salt thereof, for use in treating or preventing Central Nervous System (CNS) metastasis, brain metastasis, and/or leptomeningeal metastasis, particularly when the CNS or brain metastasis, or leptomeningeal metastasis is present in a patient with locally advanced or metastatic NSCLC.
    Type: Application
    Filed: April 17, 2019
    Publication date: May 20, 2021
    Inventors: Susan Elizabeth MOODY, Daniel Shao-Weng TAN
  • USE OF BIOMARKERS IN DETERMINING SUSCEPTIBILITY TO DISEASE TREATMENT
    Publication number: 20200318196
    Abstract: The present invention refers to a method of predicting susceptibility of a subject suffering from cancer to a treatment with an anti-cancer drug, wherein the method comprises detecting the presence or absence of a genetic alteration in a long non-coding RNA (IncRNA) that resides in an antisense strand of an oncogene, wherein the genetic alteration disrupts expression of the oncogene, and wherein the subject is predicted to be more susceptible to the treatment if the genetic alteration is present. In particular, the genetic alteration is a silent G>A mutation at Q787Q of the oncogene epidermal growth factor receptor (EGFR). Also disclosed herein is a method of treating a subject suffering from cancer, who was shown to have a genetic alteration in IncRNA that resides in an antisense strand of an oncogene.
    Type: Application
    Filed: June 5, 2017
    Publication date: October 8, 2020
    Inventors: Narayanan Gopalakrishna IYER, Daniel Shao-Weng TAN